Shots:

• The US FDA has granted FT designation to RiVax (heat stable ricin toxin vaccine) to prevent ricin intoxication. Soligenix will submit BLA for the vaccine on a rolling basis- letting the FDA review sections of the BLA prior to receiving the complete submission
• FDA’s FT designation is intended to facilitate the development and expedite the review of new drugs and biologics and is granted to the therapy
• RiVax is Soligenix's heat-stable recombinant subunit vaccine- developed to prevent exposure to ricin toxin- comprising of the genetically altered version of a Ricin Toxin A (RTA) chain containing two mutations that inactivate the toxicity of the ricin molecule

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: American Pharmacy News